BIOLASE, INC: Nasdaq/NYSE listing notice — BIOLASE avoids Nasdaq delisting but faces one-year Mandatory Panel Monitor for bid price compliance

BIOLASE, INC

Nasdaq Hearings Panel confirmed BIOLASE currently complies with continued listing requirements.
Company subject to a one-year Mandatory Panel Monitor starting August 14, 2023.
If bid price rule violated during monitor, no cure period allowed; staff issues delist determination.
Company can request a new hearing if delist determination is issued.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.82

BIOLASE, INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5815(d)(4)(B), 5550(a)(2), 5810(c)(2), 5810(c)(3), 5815(d)(4)(C)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5815(d)(4)(B), 5550(a)(2), 5810(c)(2), 5810(c)(3), 5815(d)(4)(C)

Exact text from the filing

August 14, 2023, BIOLASE, Inc. (the “Company”) received a letter (the “Letter”) from the Nasdaq Office of General Counsel confirming the decision of the Nasdaq Stock Market LLC (“Nasdaq”) Hearings Panel (the “Panel”), that the Company currently demonstrates compliance with the requirements for continued listing on The Nasdaq Capital Market. According to the Letter, pursuant to Nasdaq Listing Rule 5815(d)(4)(B), the Company will be subject to a Mandatory Panel Monitor for a period of one year from the date of this letter. If, within that one-year monitoring period, the Listing Qualifications st

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-23-212769

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.